Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects

References

• Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10(12):711–722.
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053.
   PubMed Web of Science ®Google Scholar
• Saisho Y. β-cell dysfunction: its critical role in prevention and management of type 2 diabetes. World J Diabetes. 2015;6(1):109–124.
   PubMed Web of Science ®Google Scholar
• Ali S, Davies MJ, Brady EM, et al. Guidelines for managing diabetes in Ramadan. Diabet Med. 2016;33(10):1315–1329.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 2000;133(1):73–74.
   PubMed Web of Science ®Google Scholar
• Galloway JA. Current trends in diabetes therapy. Trends Pharmacol Sci. 1984;5:33–35.
   Web of Science ®Google Scholar
• Das L, Mohan R, Makaya T. The bid to lose weight: impact of social media on weight perceptions, weight control and diabetes. Curr Diabetes Rev. 2014;10(5):291–297.
   PubMedGoogle Scholar
• Ross SA, Dzida G, Vora J, et al. Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin. 2011;27(7):1431–1438.
   PubMed Web of Science ®Google Scholar
• Ospina NS, Montori VM. Review: in type 2 diabetes, GLP-1 agonists plus basal insulin reduce HbA1c without increasing hypoglycemia. Ann Intern Med. 2015;162(2):JC6.
   PubMed Web of Science ®Google Scholar
• Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med. 2009;76 Suppl 5(Suppl 5):S28–S38.
   PubMedGoogle Scholar
• Zhong X, Chen Z, Chen Q, et al. Novel site-specific fatty chain-modified GLP-1 receptor agonist with potent antidiabetic effects. Molecules. 2019;24(4):779.
   PubMed Web of Science ®Google Scholar
• Smith EP, An Z, Wagner C, et al. The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 2014;19(6):1050–1057.
   PubMed Web of Science ®Google Scholar
• Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 2002;283(4):E745–752.
   PubMed Web of Science ®Google Scholar
• Mafong DD, Henry RR. Exenatide as a Treatment for Diabetes and Obesity: Implications for Cardiovascular Risk Reduction. Curr Atheroscler Rep. 2008;10(1):55–60.
   PubMed Web of Science ®Google Scholar
• Bunck M, Diamant MA, Eliasson B, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32(5):762–768.
   PubMed Web of Science ®Google Scholar
• Schwasinger-Schmidt T, Robbins DC, Williams SJ, et al. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats ⋆. Pharmacol Res. 2013;76:58–66.
   PubMed Web of Science ®Google Scholar
• Retnakaran R, Kramer CK, Choi H, et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care. 2014;37(12):3270–3278.
   PubMed Web of Science ®Google Scholar
• Lotte , Bjerre , Knudsen , et al. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019; 10:155.
   PubMed Web of Science ®Google Scholar
• Unciti-Broceta JD, Del Castillo T, Soriano M, et al. Novel therapy based on camelid nanobodies. Ther Deliv. 2013;4(10):1321–1336.
   PubMedGoogle Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–797.
   PubMed Web of Science ®Google Scholar
• Van Roy M, Ververken C, Beirnaert E, et al. The preclinical pharmacology of the high affinity anti-IL-6R nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015;17:135.
   PubMed Web of Science ®Google Scholar
• Delle H, Noronha IL. Induction of indoleamine 2,3-dioxygenase by gene delivery in allogeneic islets prolongs allograft survival. Am J Transplant. 2010;10(8):1918–1924.
   PubMed Web of Science ®Google Scholar
• Koh G, Suh K, Chon S, et al. The effect of cAMP-elevating agents on high glucose-induced apoptosis of isolated islets of rat pancreas. KoMCI. 2004;28:490–500.
   Google Scholar
• Zhong X, Yang S, Liu T, et al. Engineering a novel protease-based exendin-4 derivative for type 2 antidiabetic therapeutics. Eur J Med Chem. 2018;150:841–850.
   PubMed Web of Science ®Google Scholar
• Adeghate E, Ponery AS, Pallot D, et al. Distribution of serotonin and its effect on insulin and glucagon secretion in normal and diabetic pancreatic tissues in rat. Neuro Endocrinol Lett. 1999;20(5):315–322.
   PubMedGoogle Scholar
• Li L, Gao L, Wang KJ, et al. Knockin of Cre gene at Ins2 locus reveals no cre activity in mouse hypothalamic neurons. Sci Rep. 2016;6:20438.
   PubMed Web of Science ®Google Scholar
• Han J, Huang X, Sun LD, et al. Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity. Biochem Pharmacol. 2013;86(2):297–308.
   PubMed Web of Science ®Google Scholar
• Sun LD, Huang X, Han J, et al. Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity. Biochem Pharmacol. 2016;110–111:80–91.
   PubMed Web of Science ®Google Scholar
• Guo XH. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide. Curr Med Res Opin. 2016;32(1):61–76.
   PubMed Web of Science ®Google Scholar
• Parkes DG, Mace KF, Trautmann ME. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin Drug Discov. 2013;8(2):219–244.
   PubMed Web of Science ®Google Scholar
• Camastra S, Astiarraga B, Tura A, et al. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ss-cell function in non-diabetic, morbidly obese patients. Diabetes Obes Metab. 2017;19(3):412–420.
   PubMed Web of Science ®Google Scholar
• Mari A, Del Prato S, Ludvik B, et al. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes . Diabetes Obes Metab. 2016;18(8):834–839.
   PubMed Web of Science ®Google Scholar
• Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Dia Care. 2014;37(8):2159–2167.
   PubMed Web of Science ®Google Scholar
• Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004;64(8):2853–2857.
   PubMed Web of Science ®Google Scholar
• Van de Broek B, Devoogdt N, D’Hollander A, et al. Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. ACS Nano. 2011;5(6):4319–4328.
   PubMed Web of Science ®Google Scholar
• Cases AI, Ohtsuka T, Kimura H, et al. Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer. Oncol Rep. 2015;34(4):1717–1725.
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation. Prog Biophys Mol Biol. 2011;107(2):248–256.
   PubMed Web of Science ®Google Scholar
• Meena A, Michael B, Knop FK, et al. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? J Clin Endocrinol Metab. 2010;95(5):2367–2375.
   PubMed Web of Science ®Google Scholar
• Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol. 2005;288(6):R1695–1706.
   PubMed Web of Science ®Google Scholar